McCarthy Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

McCarthy Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11	Closed	-$3K	–	288
2022 Q1	$3K	Hold	11	–	–	﹤0.01%	256
2021 Q4	$2K	Buy	+11	New	+$2.14K	﹤0.01%	295

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

McCarthy Asset Management's VRTX Position: Q2 2022 in Review

McCarthy Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 11 shares — an estimated $3K sold.

McCarthy Asset Management first reported a position in VRTX in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

McCarthy Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 11 Vertex Pharmaceuticals shares in Q2 2022, an estimated $3K.
McCarthy Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 2 quarters.
McCarthy Asset Management's Vertex Pharmaceuticals position peaked at $3K in Q1 2022.
1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.